. Author manuscript; available in PMC: 2021 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2020 May 15;26(8):1402–1405. doi: 10.1016/j.bbmt.2020.04.024

Table 2.

Transplant variables and outcomes.

Variable	B2M >2.5 μg/ml (N=222)	B2M ≤ 2.5 μg/ml (N=288)	P
Received induction before ASCT, n (%)	114 (51%)	105 (36%)	0.0008
Type of induction before ASCT, n (%):
Melphalan based	11 (10%)	16 (15%)
IMiD based	13 (11%)	14 (13%)	0.3
PI based	51 (45%)	35 (33%)
Steroids/others	39 (34%)	40 (38%)
Time from diagnosis to ASCT (months), median (IQR)	3.9 (2.8–6.3)	3.9 (2.7–6.5)	0.1
Conditioning melphalan 200mg/m², n (%)	163 (73%)	241 (85%)	0.001
Mortality 100 day, n (%)	21 (9%)	9 (3%)	0.0026
Hematological response, n (%):
(≥PR)	174 (79%)	246 (85%)	0.05
(CR)	77 (35%)	125 (43%)	0.04

Abbreviations: B2M: beta-2 microglobulin, ASCT: autologous stem cell transplant, IMiD: immunomodulatory drug, PI: proteasome inhibitor, PR: partial response, CR: complete response.